5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

Autor:	J. Gligorov, X. Pivot, B. Ataseven, M. De Laurentiis, A. Llombart, K.H. Jung, A. Manikhas, H.A. Azim, A. Alexandrou, K. Gupta, L. Herraez-Baranda, N. Tosti, E. Restuccia
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Breast, Vol 56, Iss , Pp S21-S22 (2021)
Druh dokumentu:	article
ISSN:	1532-3080 0960-9776
DOI:	10.1016/S0960-9776(21)00097-7
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/cdbbced2cf6847a6a447321661688820 Zobrazit plný text záznamu Full Text from ScienceDirect View record in DOAJ